Vermillion (VRML) Receives Notice of Allowance from USPTO for Peripheral Artery Disease Patent
Tweet
Share
E-mailGet Alerts VRML Hot Sheet
Join SI Premium – FREE
Vermillion, Inc. (Nasdaq: VRML), reports the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Biomarkers for Peripheral Artery Disease."
The patent claims cover the biomarker alpha1beta glycoprotein and biomarker combinations that include alpha1beta glycoprotein for the diagnosis of PAD.
The patent claims cover the biomarker alpha1beta glycoprotein and biomarker combinations that include alpha1beta glycoprotein for the diagnosis of PAD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- NorthStrive files two patents for muscle-loss drugs in spaceflight
- Space-Eyes names four directors ahead of planned Nasdaq listing
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
